Acadia Pharmaceuticals | ACAD - Current Liabilities


Acadia Pharmaceuticals reported $305.52M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
ALKERMES USD 662.09M 62.59M Jun/2026
Alnylam Pharmaceuticals USD 1.51B 163.04M Jun/2026
Biogen USD 3.92B 918.2M Jun/2026
BioMarin Pharmaceutical USD 793.15M 34.12M Mar/2026
Bristol-Myers Squibb USD 18.66B 499M Jun/2026
Cara Therapeutics USD 11.26M 216K Mar/2026
Corcept Therapeutics USD 153.8M 4.62M Jun/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Eisai JPY 393.64B 53.39B Jun/2026
Eli Lilly USD 36.63B 1.41B Mar/2026
Incyte USD 1.31B 177.55M Jun/2026
J&J USD 54.9B 2.82B Jun/2026
Moderna USD 2.53B 139M Jun/2026
Neurocrine Biosciences USD 874.5M 42.8M Jun/2026
Pfizer USD 34.35B 2.64B Mar/2026
Prothena USD 32.52M 8.33M Mar/2026
PTC Therapeutics USD 771.07M 152.54M Jun/2026
Sarepta Therapeutics USD 499.16M 596.13M Mar/2026
Ultragenyx Pharmaceutical USD 325M 59M Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025
Vertex Pharmaceuticals USD 3.88B 19.4M Mar/2026